The Vector Meson Form Factor Analysis in Light-Front Dynamics

We study the form factors of vector mesons using a covariant fermion field theory model in $(3+1)$ dimensions. Performing a light-front calculation in the $q^+ =0$ frame in parallel with a manifestly covariant calculation, we note the existence of a nonvanishing zero-mode contribution to the light-front current $J^+$ and find a way of avoiding the zero-mode in the form factor calculations. Upon choosing the light-front gauge (\ep^+_{h=\pm}=0) with circular polarization and with spin projection $h=\uparrow\downarrow=\pm$, only the helicity zero to zero matrix element of the plus current receives zero-mode contributions. Therefore, one can obtain the exact light-front solution of the form factors using only the valence contribution if only the helicity components, $(h'h)=(++),(+-)$, and $(+0)$, are used. We also compare our results obtained from the light-front gauge in the light-front helicity basis (i.e. $h=\pm,0$) with those obtained from the non-LF gauge in the instant form linear polarization basis (i.e. $h=x,y,z$) where the zero-mode contributions to the form factors are unavoidable.Comment: 33 pages; typo in Eq.(15) is corrected; comment on Ref.[9] is corrected; version to appear in Phys. Rev.

Feasibility of controlling hookworm infection through preventive chemotherapy: a simulation study using the individual-based WORMSIM modelling framework

Background: Globally, hookworms infect 440 million people in developing countries. Especially children and women of childbearing age are at risk of developing anaemia as a result of infection. To control hookworm infection and disease (i.e. reduce the prevalence of medium and heavy infection to <1 %), the World Health Organization has set the target to provide annual or semi-annual preventive chemotherapy (PC) with albendazole (ALB) or mebendazole (MEB) to at least 75 % of all children and women of childbearing age in endemic areas by 2020. Here, we predict the feasibility of achieving <1 % prevalence of medium and heavy infection, based on simulations with an individual-based model. Methods: We developed WORMSIM, a new generalized individual-based modelling framework for transmission and control of helminths, and quantified it for hookworm transmission based on published data. We simulated the impact of standard and more intense PC strategies on trends in hookworm infection, and explored the potential additional impact of interventions that improve access to water, sanitation, and hygiene (WASH). The individual-based framework allowed us to take account of inter-individual heterogeneities in exposure and contribution to transmission of infection, as well as in participation in successive PC rounds. Results: We predict that in low and medium endemic areas, current PC strategies (including targeting of WCBA) will achieve control of hookworm infection (i.e. the parasitological target) within 2 years. In highly endemic areas, control can be achieved with semi-annual PC with ALB at 90 % coverage, combined with interventions that reduce host contributions to the environmental reservoir of infection by 50 %. More intense PC strategies (high frequency and coverage) can help speed up control of hookworm infection, and may be necessary in some extremely highly endemic settings, but are not a panacea against systematic non-participation to PC. Conclusions: Control of hookworm infection by 2020 is feasible with current PC strategies (including targeting of WCBA). In highly endemic areas, PC should be combined with health education and/or WASH interventions

Three-boson relativistic bound states with zero-range interaction

For the zero-range interaction providing a given mass M_2 of the two-body bound state, the mass M_3 of the relativistic three-boson state is calculated. We have found that the three-body system exists only when M_2 is greater than a critical value M_c approximately 1.43 m (m is the constituent mass). For M_2=M_c the mass M_3 turns into zero and for M_2<M_c there is no solution with real value of M_3.Comment: 7 pages, 4 figure

Transition Form Factors between Pseudoscalar and Vector Mesons in Light-Front Dynamics

We study the transition form factors between pseudoscalar and vector mesons using a covariant fermion field theory model in $(3+1)$ dimensions. Performing the light-front calculation in the $q^+ =0$ frame in parallel with the manifestly covariant calculation, we note that the suspected nonvanishing zero-mode contribution to the light-front current $J^+$ does not exist in our analysis of transition form factors. We also perform the light-front calculation in a purely longitudinal $q^+ > 0$ frame and confirm that the form factors obtained directly from the timelike region are identical to the ones obtained by the analytic continuation from the spacelike region. Our results for the $B \to D^* l \nu_l$ decay process satisfy the constraints on the heavy-to-heavy semileptonic decays imposed by the flavor independence in the heavy quark limit.Comment: 20 pages, 14 figure

Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality

BACKGROUND: Oxidative stress has been suggested to play a key role in the development of cardiovascular disease (CVD). The aim of our study was to investigate the associations of serum peroxiredoxin 4 (Prx4), a hydrogen peroxide-degrading peroxidase, with incident CVD and all-cause mortality. We subsequently examined the incremental value of Prx4 for the risk prediction of CVD compared with the Framingham risk score (FRS). METHODS AND RESULTS: We performed Cox regression analyses in 8141 participants without history of CVD (aged 28 to 75 years; women 52.6%) from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study in Groningen, The Netherlands. Serum Prx4 was measured by an immunoluminometric assay in baseline samples. Main outcomes were: (1) incident CVD events or CVD mortality and (2) all-cause mortality during a median follow-up of 10.5 years. In total, 708 participants (7.8%) developed CVD events or CVD mortality, and 517 participants (6.3%) died. Baseline serum Prx4 levels were significantly higher in participants with incident CVD events or CVD mortality and in those who died than in participants who remained free of outcomes (both P<0.001). In multivariable models with adjustment for Framingham risk factors, hazard ratios were 1.16 (95% CI 1.06 to 1.27, P<0.001) for incident CVD events or CVD mortality and 1.17 (95% CI 1.06 to 1.29, P=0.003) for all-cause mortality per doubling of Prx4 levels. After the addition of Prx4 to the FRS, the net reclassification improvement was 2.7% (P=0.01) using 10-year risk categories of CVD. CONCLUSIONS: Elevated serum Prx4 levels are associated with a significantly higher risk of incident CVD events or CVD mortality and all-cause mortality after adjustment for clinical risk factors. The addition of Prx4 to the FRS marginally improved risk prediction of future CVD